• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 258

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

Using a Casing Layer for Growing Magic Mushrooms – Why Bother?

Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004...

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

PT239 – Richie Ogulnick – Ibogaine, Unicity, and Beneficence

PsyBio Therapeutics Announces Application to List on OTCQX

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s...

Awakn launches Digital unit and signs agreement with the University of...

Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA...

COVID-19 and Psychedelic Group Work: It’s Still Too Soon

1...257258259...294Page 258 of 294

EDITOR PICKS

From Huxley to Heffter: Mark Geyer Reflects on a Life in...

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©